

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	63,339	85.4%	3,814	94.3%	22,466	97.7%	1,766	21.6%	3,088	95.8%
Squamous cell carcinoma (8070-8078,8083-8084)	61,917	83.5%	3,608	89.2%	22,108	96.1%	1,685	20.6%	3,055	94.8%
Adenocarcinoma ^c	7,315	9.9%	166	4.1%	277	1.2%	5,108	62.5%	109	3.4%
Other specific carcinomas ^d	673	0.9%	-	-	65	0.3%	414	5.1%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,948	2.6%	-	-	104	0.5%	550	6.7%	-	-
Sarcoma and soft tissue ^e	233	0.3%	-	-	34	0.1%	53	0.6%	-	-
Other specific types ^f	413	0.6%	36	0.9%	-	-	205	2.5%	-	-
Unspecified (8000-8005)	244	0.3%	-	-	42	0.2%	76	0.9%	-	-
Total	74,166	100.0%	4,044	100.0%	23,000	100.0%	8,172	100.0%	3,224	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	8,194	82.7%	2,605	67.2%	16,315	98.3%	3,677	97.3%	1,414	90.0%
Squamous cell carcinoma (8070-8078,8083-8084)	7,805	78.8%	2,454	63.3%	16,150	97.3%	3,648	96.5%	1,404	89.4%
Adenocarcinoma ^c	1,400	14.1%	122	3.1%	86	0.5%	21	0.6%	26	1.7%
Other specific carcinomas ^d	46	0.5%	38	1.0%	47	0.3%	33	0.9%	17	1.1%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	70	0.7%	1,037	26.7%	88	0.5%	23	0.6%	59	3.8%
Sarcoma and soft tissue ^e	46	0.5%	46	1.2%	17	0.1%	17	0.4%	-	-
Other specific types ^f	125	1.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	23	0.2%	16	0.4%	28	0.2%	-	-	42	2.7%
Total	9,905	100.0%	3,878	100.0%	16,592	100.0%	3,780	100.0%	1,571	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.